UBS raised the firm’s price target on Axsome Therapeutics (AXSM) to $251 from $248 and keeps a Buy rating on the shares. Axsome is seeing significant operating leverage due to the “attractive” ADA launch, despite the meaningful salesforce expansion, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $207 from $204 at Morgan Stanley
- Axsome announces first patient dosed in CLARITY Phase 3 trial of solriamfetol
- Axsome Therapeutics price target raised to $220 from $205 at Guggenheim
- Axsome Therapeutics price target raised to $202 from $193 at Wells Fargo
- Axsome Therapeutics: Auvelity Growth and Alzheimer’s Agitation Upside Support Buy Rating and $214 Target